PMC:7534795 / 30796-31024 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T153","span":{"begin":128,"end":135},"obj":"Body_part"},{"id":"T154","span":{"begin":144,"end":151},"obj":"Body_part"},{"id":"T155","span":{"begin":195,"end":200},"obj":"Body_part"},{"id":"T156","span":{"begin":219,"end":226},"obj":"Body_part"}],"attributes":[{"id":"A153","pred":"fma_id","subj":"T153","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A154","pred":"fma_id","subj":"T154","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A155","pred":"fma_id","subj":"T155","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A156","pred":"fma_id","subj":"T156","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T57","span":{"begin":195,"end":200},"obj":"Body_part"}],"attributes":[{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T248","span":{"begin":2,"end":14},"obj":"Disease"},{"id":"T249","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"T250","span":{"begin":82,"end":91},"obj":"Disease"},{"id":"T251","span":{"begin":175,"end":208},"obj":"Disease"},{"id":"T252","span":{"begin":175,"end":187},"obj":"Disease"},{"id":"T253","span":{"begin":195,"end":208},"obj":"Disease"}],"attributes":[{"id":"A248","pred":"mondo_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/MONDO_0001531"},{"id":"A249","pred":"mondo_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A250","pred":"mondo_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A251","pred":"mondo_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/MONDO_0001302"},{"id":"A252","pred":"mondo_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A253","pred":"mondo_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/MONDO_0005267"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T92107","span":{"begin":48,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T4831","span":{"begin":195,"end":200},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T34951","span":{"begin":195,"end":200},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T52443","span":{"begin":195,"end":200},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T98069","span":{"begin":195,"end":200},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T227","span":{"begin":128,"end":135},"obj":"Chemical"},{"id":"T228","span":{"begin":144,"end":151},"obj":"Chemical"},{"id":"T229","span":{"begin":219,"end":226},"obj":"Chemical"}],"attributes":[{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-sentences","denotations":[{"id":"T214","span":{"begin":44,"end":63},"obj":"Sentence"},{"id":"T215","span":{"begin":64,"end":91},"obj":"Sentence"},{"id":"T216","span":{"begin":92,"end":157},"obj":"Sentence"},{"id":"T217","span":{"begin":158,"end":208},"obj":"Sentence"},{"id":"T218","span":{"begin":209,"end":226},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T127","span":{"begin":2,"end":14},"obj":"Phenotype"},{"id":"T128","span":{"begin":175,"end":187},"obj":"Phenotype"}],"attributes":[{"id":"A127","pred":"hp_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/HP_0003256"},{"id":"A128","pred":"hp_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}

{"project":"LitCovid-PubTator","denotations":[{"id":"971","span":{"begin":128,"end":135},"obj":"Chemical"},{"id":"972","span":{"begin":144,"end":151},"obj":"Chemical"},{"id":"987","span":{"begin":2,"end":14},"obj":"Disease"},{"id":"988","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"989","span":{"begin":115,"end":124},"obj":"Disease"},{"id":"990","span":{"begin":175,"end":187},"obj":"Disease"},{"id":"991","span":{"begin":195,"end":213},"obj":"Disease"}],"attributes":[{"id":"A971","pred":"tao:has_database_id","subj":"971","obj":"MESH:D006493"},{"id":"A972","pred":"tao:has_database_id","subj":"972","obj":"MESH:D006493"},{"id":"A987","pred":"tao:has_database_id","subj":"987","obj":"MESH:D001778"},{"id":"A988","pred":"tao:has_database_id","subj":"988","obj":"MESH:C000657245"},{"id":"A989","pred":"tao:has_database_id","subj":"989","obj":"MESH:D003643"},{"id":"A990","pred":"tao:has_database_id","subj":"990","obj":"MESH:D006973"},{"id":"A991","pred":"tao:has_database_id","subj":"991","obj":"MESH:D006331"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d coagulopathy • Retrospective cohort study\n• ≥ 18 years of age\n• Severe COVID-19 infection\n• Evaluation of 28-day mortality in heparin and non-heparin users\n• 48.5% comorbid hypertension and/or heart disease\n• N = 99 heparin\n•"}